The tweet was deleted by the author.
But we saved everything 🙂.
Bicara Therapeutics has launched its FORTIFI-FLEX clinical trial to evaluate a new dosing approach for patients with recurrent or metastatic HPV-negative head and neck squamous cell carcinoma.
The study involves an initial weekly loading dose administered over 12 weeks, followed by an every-three-week maintenance regimen in the first-line setting. The trial aims to assess outcomes in a particularly challenging patient population.
View post on X Loading...